A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus

Brandler, Samantha; Ruffié, Claude; Combredet, Chantal; Brault, Jean‐Baptiste; Najburg, Valérie; Prévost, Marie‐Christine; Habel, André; Tauber, Erich; Desprès, Philippe; Tangy, Frédéric

doi:10.1016/j.vaccine.2013.05.086

Cited by 136 publications

(150 citation statements)

References 51 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, arthralgia manifests itself as pain of the joints, but it is hard to assess the degree of pain in animals we manipulated after anesthesia, taking into account that, in humans, its degree of severity is more dependent on self-perception than external scaling. Recently, two clinical trials were conducted evaluating two CHIKV vaccine platforms, one based on virus-like particles (VLPs) (29,49) and the other on a recombinant measles virus (50,51). Both were immunogenic and safe but required at least two immunizations to achieve substantial antibody responses.…”

Section: Discussionmentioning

confidence: 99%

Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus

et al. 2017

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus

et al. 2017

View full text Add to dashboard Cite

“…195). In preclinical studies using Ifnar -/-mice, MV-CHIKV elicited robust and cross-neutralizing immune responses that protect against lethal challenge (195). In a phase I clinical trial of MV-CHIKV, neutralizing antibodies were detected in a dose-dependent manner with 100% seroconversion after booster immunization in all three dose cohorts, despite the presence of preexisting antivector immunity (196).…”

Section: Acknowledgmentsmentioning

confidence: 99%

Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies

Silva¹,

Dermody²

2017

Journal of Clinical Investigation

311

338

View full text Add to dashboard Cite

“…Several CHIKV vaccine candidates are under development (9), including attenuated (10)(11)(12)(13)(14)(15)(16) or inactivated (17)(18)(19) CHIKV, alphavirus chimeras (20)(21)(22), and subunit (23)(24)(25)(26)(27) and genetic (21,(28)(29)(30)(31) vaccines. Moreover, we have reported previously on the construction and preclinical evaluation of novel CHIKV vaccine candidates, based on attenuated CHIKV (12) or recombinant modified vaccinia virus Ankara (MVA) expressing CHIKV antigens (MVA-CHIKV) (29), that were able to induce strong immunogenicity and efficacy in a mouse model.…”

Section: Hikungunya Virus (Chikv) Is An Alphavirus Of the Familymentioning

confidence: 99%

Prime-Boost Immunization Strategies against Chikungunya Virus

Holzmann

Lum

Kümmerer

et al. 2014

J Virol

View full text Add to dashboard Cite

Chikungunya virus (CHIKV) is a reemerging mosquito-borne alphavirus that causes debilitating arthralgia in humans. Here we describe the development and testing of novel DNA replicon and protein CHIKV vaccine candidates and evaluate their abilities to induce antigen-specific immune responses against CHIKV. We also describe homologous and heterologous prime-boost immunization strategies using novel and previously developed CHIKV vaccine candidates. Immunogenicity and efficacy were studied in a mouse model of CHIKV infection and showed that the DNA replicon and protein antigen were potent vaccine candidates, particularly when used for priming and boosting, respectively. Several prime-boost immunization strategies eliciting unmatched humoral and cellular immune responses were identified. Further characterization by antibody epitope mapping revealed differences in the qualitative immune responses induced by the different vaccine candidates and immunization strategies. Most vaccine modalities resulted in complete protection against wild-type CHIKV infection; however, we did identify circumstances under which certain immunization regimens may lead to enhancement of inflammation upon challenge. These results should help guide the design of CHIKV vaccine studies and will form the basis for further preclinical and clinical evaluation of these vaccine candidates. IMPORTANCE As of today, there is no licensed vaccine to prevent CHIKV infection. In considering potential new vaccine candidates, a vaccinethat could raise long-term protective immunity after a single immunization would be preferable. While humoral immunity seems to be central for protection against CHIKV infection, we do not yet fully understand the correlates of protection. Therefore, in the absence of a functional vaccine, there is a need to evaluate a number of different candidates, assessing their merits when they are used either in a single immunization or in a homologous or heterologous prime-boost modality. Here we show that while single immunization with various vaccine candidates results in potent responses, combined approaches significantly enhance responses, suggesting that such approaches need to be considered in the further development of an efficacious CHIKV vaccine.

show abstract

A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus

Cited by 136 publications

References 51 publications

Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus

Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus

Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies

Prime-Boost Immunization Strategies against Chikungunya Virus

Contact Info

Product

Resources

About